Called CanPathPro, the research consortium aims to combine omics data and systems biology tools into a single commercial platform for testing cancer hypotheses.
The group will offer free access to omic and clinical data from the project and develop software to help clinicians use the models in patient care.
The partners have planned a three-year pilot and selected three NCI projects to benefit from supercomputers and expertise offered by four DOE labs.
Myriad Genetics, Kinaxo Biotechnologies, Bavarian Research Foundation, European Commission, Decode Genetics, Ontario Institute for Cancer Research
The $3.8 million program will back assay development, screening tools, toxicity, and elucidation of 3D structures in search of HIV treatments
In Science this week: genetic target for urothelial bladder cancer treatment, and more.
At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.
Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.
Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.